PT Modifier
Colorectal cancer screening test; converted to diagnostic test or other procedure
HCPCS modifierPT
- Description
- Colorectal cancer screening test; converted to diagnostic test or other procedure
- Short description
- Clrctal screen to diagn
- Added
- January 1, 2011
- Last change
- January 1, 2011
What does the PT modifier mean?
The HCPCS Level II modifier PT means: “Colorectal cancer screening test; converted to diagnostic test or other procedure”. Append it to a HCPCS or CPT code on the claim line when the payer’s policy calls for it; placement and payment effects are defined by each payer.
Other P modifiers
- P1 – A normal healthy patient
- P2 – A patient with mild systemic disease
- P3 – A patient with severe systemic disease
- P4 – A patient with severe systemic disease that is a constant threat to life
- P5 – A moribund patient who is not expected to survive without the operation
- P6 – A declared brain-dead patient whose organs are being removed for donor purposes
- PA – Surgical or other invasive procedure on wrong body part
- PB – Surgical or other invasive procedure on wrong patient
- PC – Wrong surgery or other invasive procedure on patient
- PD – Diagnostic or related non diagnostic item or service provided in a wholly owned or operated entity to a patient who is admitted as an inpatient within 3 days
- PI – Positron emission tomography (pet) or pet/computed tomography (ct) to inform the initial treatment strategy of tumors that are biopsy proven or strongly suspected of being cancerous based on other diagnostic testing
- PL – Progressive addition lenses
- PM – Post mortem
- PN – Non-excepted service provided at an off-campus, outpatient, provider-based department of a hospital
- PO – Excepted service provided at an off-campus, outpatient, provider-based department of a hospital
- PS – Positron emission tomography (pet) or pet/computed tomography (ct) to inform the subsequent treatment strategy of cancerous tumors when the beneficiary's treating physician determines that the pet study is needed to inform subsequent anti-tumor strategy